The treatment is now just a step away from being the first ever allogeneic stem cell therapy approved ... in a Phase 1/2 trial in acute myocardial infarction.

Takeda is to acquire TiGenix, the stem cell specialist biotech with which it has developed a gastro stem cell therapy, in a deal worth 520 million euros ($626 million). The decision follows ...

Heart muscle cells grown from stem cells show promise in monkeys with a heart problem that typically results from a heart ...

Researchers led by Osaka University in Japan have conducted the first human trial using induced pluripotent stem-cell-derived ...

Researchers found that neural crest stem cells are uniquely capable of reprogramming, challenging current reprogramming ...

Researchers successfully tested the safety and preliminary efficacy of stem-cell-derived corneal implants, showing promise ...

Three individuals with vision disabilities experienced eyesight improvements after receiving stem-cell transplants targeting ...

Aging is inevitable for most cell types in the human body, but hematopoietic stem cells (HSCs) seem to defy the process. They ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Clinicians will soon gain access to trusted education on stem cell-based therapies through a new Continuing Education (CE) course developed by the International Society of Stem Cell Research (ISSCR).